Evolus, Inc. (NASDAQ:EOLS) CMO Tomoko Yamagishi-Dressler Sells 4,536 Shares

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $60,147.36. Following the completion of the transaction, the chief marketing officer now owns 95,671 shares in the company, valued at $1,268,597.46. This trade represents a 4.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Evolus Stock Down 0.2 %

Shares of NASDAQ:EOLS traded down $0.03 during trading on Monday, reaching $13.00. 527,427 shares of the stock were exchanged, compared to its average volume of 591,935. Evolus, Inc. has a 1-year low of $9.25 and a 1-year high of $17.82. The stock has a fifty day moving average of $13.42 and a two-hundred day moving average of $13.87. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The firm has a market cap of $826.63 million, a price-to-earnings ratio of -14.29 and a beta of 1.28.

Institutional Investors Weigh In On Evolus

A number of institutional investors and hedge funds have recently made changes to their positions in the business. KBC Group NV purchased a new stake in shares of Evolus in the fourth quarter worth approximately $49,000. IFP Advisors Inc grew its holdings in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after buying an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Evolus in the 4th quarter valued at $106,000. Rafferty Asset Management LLC bought a new position in Evolus during the 4th quarter valued at $115,000. Finally, Quantbot Technologies LP purchased a new position in Evolus during the 4th quarter worth $118,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts recently commented on EOLS shares. HC Wainwright reaffirmed a "buy" rating and set a $27.00 target price on shares of Evolus in a research note on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Evolus in a report on Wednesday, March 5th. Finally, Barclays lifted their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.